Spots Global Cancer Trial Database for Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Extended Adjuvant Treatment With Letrozole in Breast Cancer Who Complete 5 Years of Toremifene
Official Title: Evaluate Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Have Completed 5 Years of Toremifene
Study ID: NCT01072318
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess Efficacy and Safety of Extended Adjuvant Treatment With Letrozole in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years of Toremifene
Detailed Description: 1. Primary purpose To evaluate disease free survival rate (DFS) after taking 36 months with Letrozole in postmenopausal women with hormone receptor positive breast cancer who complete 5 years of Toremifene 2. Secondary purpose * To evaluate follows after taking 36 months with Letrozole in postmenopausal women with hormone receptor positive breast cancer who complete 5 years of Toremifene. 1. Disease Free Survival rate(DFS)-12 months, 24 months 2. Distant disease free survival rate(DDFS), Overall Survival(OS) * 12 months, 24 months, 36 months c. safety * Change of lipid profiles * Mortality and morbidity due to Cardiovascular disease * Incidence of Fracture * Change of Bone density * Common toxic effect
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Department of Surgery, Asan medical center, Seoul, , Korea, Republic of
Contact Details
Name: Sei-Hyun Ahn, MD
Affiliation: Department of Surgery, Asan medical center, South Korea
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
